| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Cancer statistics, 2010.
|
CA Cancer J Clin
|
2010
|
103.28
|
|
2
|
Molecular characterisation of soft tissue tumours: a gene expression study.
|
Lancet
|
2002
|
7.05
|
|
3
|
Soft-tissue sarcomas in adults.
|
N Engl J Med
|
2005
|
5.97
|
|
4
|
Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration.
|
Lancet
|
1997
|
4.45
|
|
5
|
The evolving classification of soft tissue tumours: an update based on the new WHO classification.
|
Histopathology
|
2006
|
4.14
|
|
6
|
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
|
J Clin Oncol
|
2009
|
3.41
|
|
7
|
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.
|
J Clin Oncol
|
2005
|
2.39
|
|
8
|
Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients.
|
J Clin Oncol
|
2001
|
2.29
|
|
9
|
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.
|
J Clin Oncol
|
2004
|
2.27
|
|
10
|
Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity.
|
J Clin Oncol
|
2000
|
2.22
|
|
11
|
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update.
|
Nat Rev Clin Oncol
|
2015
|
2.02
|
|
12
|
Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome.
|
J Clin Oncol
|
2003
|
1.94
|
|
13
|
Fusions of the SYT and SSX genes in synovial sarcoma.
|
Oncogene
|
2001
|
1.59
|
|
14
|
Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres.
|
Eur J Nucl Med Mol Imaging
|
2010
|
1.51
|
|
15
|
Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
|
Clin Cancer Res
|
1996
|
1.47
|
|
16
|
Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation.
|
Am J Pathol
|
2002
|
1.46
|
|
17
|
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
|
Eur J Cancer
|
2010
|
1.43
|
|
18
|
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.
|
Blood
|
2005
|
1.41
|
|
19
|
Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray.
|
Cancer Res
|
2002
|
1.37
|
|
20
|
A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens.
|
Oncologist
|
2008
|
1.31
|
|
21
|
Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival.
|
J Clin Oncol
|
1996
|
1.30
|
|
22
|
Developmental pathways in colon cancer: crosstalk between WNT, BMP, Hedgehog and Notch.
|
Cell Cycle
|
2012
|
1.26
|
|
23
|
Molecular classification of soft tissue sarcomas and its clinical applications.
|
Int J Clin Exp Pathol
|
2010
|
1.15
|
|
24
|
The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis.
|
J Pharmacol Exp Ther
|
2010
|
1.09
|
|
25
|
Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?
|
Eur J Nucl Med Mol Imaging
|
2011
|
1.09
|
|
26
|
Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling.
|
Br J Cancer
|
2003
|
1.08
|
|
27
|
Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma.
|
Q J Nucl Med Mol Imaging
|
2008
|
1.08
|
|
28
|
90Y Bremsstrahlung imaging for absorbed-dose assessment in high-dose radioimmunotherapy.
|
J Nucl Med
|
2010
|
1.03
|
|
29
|
Radioimmunotherapy of non-Hodgkin lymphomas.
|
Blood
|
2002
|
1.03
|
|
30
|
Therapeutic potential of antibodies against FZD 10, a cell-surface protein, for synovial sarcomas.
|
Oncogene
|
2005
|
1.00
|
|
31
|
Embryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targeting.
|
Sarcoma
|
2012
|
0.99
|
|
32
|
Fast simulation of yttrium-90 bremsstrahlung photons with GATE.
|
Med Phys
|
2010
|
0.96
|
|
33
|
Cancer stem cell plasticity and tumor hierarchy.
|
World J Stem Cells
|
2015
|
0.96
|
|
34
|
Pharmacokinetics of therapeutic monoclonal antibodies used in oncology.
|
Anticancer Res
|
2005
|
0.96
|
|
35
|
Advancing role of radiolabeled antibodies in the therapy of cancer.
|
Cancer Immunol Immunother
|
2003
|
0.95
|
|
36
|
Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
|
J Nucl Med
|
2006
|
0.95
|
|
37
|
Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5.
|
Bioconjug Chem
|
2000
|
0.94
|
|
38
|
The rationale for targeted therapies in medulloblastoma.
|
Neuro Oncol
|
2013
|
0.92
|
|
39
|
High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial.
|
Clin Cancer Res
|
2000
|
0.91
|
|
40
|
Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial.
|
Lung Cancer
|
2004
|
0.91
|
|
41
|
[Incidence rate, epidemiology of sarcoma and molecular biology. Preliminary results from EMS study in the Rhône-Alpes region].
|
Bull Cancer
|
2010
|
0.89
|
|
42
|
Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10.
|
Cancer Sci
|
2008
|
0.88
|
|
43
|
MR imaging of soft tissue tumors and tumor-like lesions.
|
Pediatr Radiol
|
2003
|
0.86
|
|
44
|
Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy.
|
Cancer Discov
|
2015
|
0.86
|
|
45
|
Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab.
|
J Nucl Med
|
2010
|
0.86
|
|
46
|
Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers.
|
Urology
|
2000
|
0.85
|
|
47
|
Radioimmunotherapy of non-Hodgkin's lymphoma: clinical development of the Zevalin regimen.
|
Biotechnol Annu Rev
|
2004
|
0.85
|
|
48
|
Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10: therapeutic efficacy largely depends on radiosensitivity.
|
Ann Nucl Med
|
2009
|
0.83
|
|
49
|
Molecular cloning of Frizzled-10, a novel member of the Frizzled gene family.
|
Biochem Biophys Res Commun
|
1999
|
0.83
|
|
50
|
Imaging and phase I study of 111In- and 90Y-labeled anti-LewisY monoclonal antibody B3.
|
Clin Cancer Res
|
2000
|
0.80
|
|
51
|
Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.
|
Clin Cancer Res
|
1999
|
0.78
|
|
52
|
On clonogenic tumour cells and metastasis-forming cells.
|
Nat Rev Cancer
|
2008
|
0.77
|
|
53
|
Block co-polymeric magnetic resonance contrast agents.
|
Invest Radiol
|
1994
|
0.77
|
|
54
|
Wnt/β-catenin pathway in tissue injury: roles in pathology and therapeutic opportunities for regeneration.
|
FASEB J
|
2016
|
0.77
|
|
55
|
Translational and clinical implications of the genetic landscape of prostate cancer.
|
Nat Rev Clin Oncol
|
2016
|
0.76
|
|
56
|
Radioimmunodiagnosis and therapy.
|
Cancer Treat Rev
|
2000
|
0.75
|
|
57
|
Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature.
|
Nucl Med Commun
|
1999
|
0.75
|